The FDA granted priority review to obinutuzumab for relapsing/steroid-dependent pediatric INS, based on phase 3 INShore remission data
Keisha L. Gibson, MD, MPH
Advertisement
Keisha L. Gibson, MD, MPH, pediatric nephrologist at the University of North Carolina School of Medicine.
Articles by Keisha L. Gibson, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA presses infant formula makers to tighten supplier oversight after botulism and cereulide events
2
ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids
3
FDA accepts sNDA for vosoritide in children with achondroplasia
4
RSV Immunization Rates and Vaccine Hesitancy: Practical Strategies for Clinicians
5